UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 29, 2020
ENDONOVO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-55453 | 45-2552528 | ||
|
(State
or other jurisdiction of
incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
6320 Canoga Avenue, 15th Floor
Woodland Hills, CA 91367
(Address of principal executive office)(Zip Code)
Registrant’s telephone number, including area code: (800) 489-4774
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| Common Stock, par value $0.0001 | ENDV | OTCQB |
Item 3.03 Material Modification to Rights of Security Holders.
On January 29, 2020, the Delaware Secretary of State filed the Registrant’s Amended and Restated Certificate of Designation (the “Amendment”) for its Series C Secured Redeemable Preferred Stock (the “C Stock”). The Amendment changed the rights of the C Stock by: (i) removing the requirement that the Registrant redeem the C Stock; (ii) removing the obligation of the Registrant to pay dividends on the C Stock; and (iii) allowing holders of shares of C Stock to convert the stated value of their shares of C Stock ($1,000 per share) into common stock of the Registrant at 75% of the closing price of such common stock on the day prior to the conversion. The foregoing is not a detailed description of the changes affected by the Amendment and is qualified in its entirety by the Amendment, which is file as an exhibit to this report.
The Amendment was approved by the Registrant’s director and by the holders of 933 of the 1,814 outstanding shares of C Stock or 51.4%.
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements
None
(b) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 3, 2020
| ENDONOVO THERAPEUTICS, INC. | ||
| By: | /s/ Alan Collier | |
| Alan Collier | ||
| Chief Executive Officer | ||
